Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
Open Access
- 20 May 2019
- journal article
- conference paper
- Published by Wolters Kluwer Health in Menopause
- Vol. 26 (9) , 994-1001
Abstract
Objective: To prospectively evaluate the effects of ospemifene on the vulva and vagina in postmenopausal women using vulvar-vestibular photography and direct visual assessments. Methods: Postmenopausal women (aged 40-80 years) with moderate to severe vaginal dryness as their most bothersome symptom (MBS) were randomized to daily ospemifene 60 mg or placebo in this 12-week, multicenter, double-blind, phase 3 study. Vulvar-vestibular photographic images were captured at baseline and week 12 and were independently assessed with the Vulvar Imaging Assessment Scale (VIAS). Changes from baseline in Vaginal and Vulvar Health Indices (VHI and VuHI) with ospemifene versus placebo were analyzed at weeks 4, 8, and 12. Correlations between VIAS, VHI, and VuHI, with vaginal dryness severity and the Female Sexual Function Index (FSFI) scores were also assessed. Results: In all, 631 eligible participants were randomized (ospemifene 316, placebo 315) and included in the intention-to-treat population. Compared with placebo, ospemifene significantly improved total scores for VIAS (P = 0.0154), VHI (P < 0.0001), and VuHI (P < 0.0001) from baseline to week 12; significant VHI (P < 0.0001) and VuHI (P = 0.002) improvements were observed at week 4. Most VHI and VuHI individual items were significantly better with ospemifene versus placebo at week 12 (P < 0.05). Most correlations between the vulvovaginal assessment total scores versus vaginal dryness severity and FSFI scores were significant (P < 0.05). Conclusion: Improvements observed in vulvovaginal health with ospemifene assessed by prospective vulvar-vestibular photography and other direct visual assessments support its efficacy in addition to the treatment of moderate to severe vaginal dryness due to menopause and the use of photographic and direct visual evaluations in future clinical trials. Video Summary: Supplemental Digital Content 1, http://links.lww.com/MENO/A415Keywords
This publication has 19 references indexed in Scilit:
- Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trialMenopause, 2019
- Couplepause: A New Paradigm in Treating Sexual Dysfunction During Menopause and AndropauseSexual Medicine Reviews, 2018
- The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA studyMaturitas, 2018
- Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE SurveyClimacteric, 2015
- The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophyClimacteric, 2014
- Clinical photography and our responsibilitiesIndian Journal of Plastic Surgery, 2014
- Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trialMaturitas, 2014
- Vaginal health in the United StatesMenopause, 2013
- Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) SurveyThe Journal of Sexual Medicine, 2013
- Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapyInternational Journal of Women's Health, 2009